POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Seq. Identity (%)	View	Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1ccz	PROTEIN (CD58) (Homo sapiens)	5 / 9	LEU A  67 LEU A  90 VAL A  35 ALA A  36 PHE A  15	None	1.13A	17.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1d7w	MYELOPEROXIDASE (Homo sapiens)	5 / 9	TYR C 334 LEU A  97 LEU A  93 ALA C 496 PHE C 503	HEM  A 605 ( 4.8A) None None None None	1.23A	19.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	5 / 9	TYR A 211 VAL A 380 LEU A 401 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) IBM  A 503 (-4.7A) None IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.79A	29.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2pkd	SLAM FAMILY MEMBER 5 (Homo sapiens)	5 / 9	LEU A  79 LEU A 106 VAL A  40 ALA A  41 PHE A  19	None	1.05A	15.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2rt5	MSX2-INTERACTING PROTEIN (Homo sapiens)	5 / 9	LEU A3639 LEU A3575 VAL A3563 LEU A3555 GLN A3627	None	1.29A	21.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2y0n	MALE-SPECIFIC LETHAL 1 HOMOLOG MALE-SPECIFIC LETHAL 3 HOMOLOG (Homo sapiens; Mus musculus)	5 / 9	LEU A 463 LEU A 261 ALA A 479 LEU A 477 PHE E 577	None	1.08A	21.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 9	TYR A 612 LEU A 725 LEU A 765 VAL A 782 ALA A 783 MET A 816 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) None VDN  A   1 ( 4.7A) VDN  A   1 ( 4.7A) VDN  A   1 ( 4.0A) VDN  A   1 (-4.0A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.36A	94.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 9	TYR A 612 LEU A 725 LEU A 765 VAL A 782 ALA A 783 GLN A 817 PHE A 820	None None WAN  A 901 ( 4.7A) WAN  A 901 ( 4.9A) WAN  A 901 (-3.6A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.28A	37.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 9	TYR A 612 LEU A 725 LEU A 765 VAL A 782 MET A 816 GLN A 817 PHE A 820	None None WAN  A 901 ( 4.7A) WAN  A 901 ( 4.9A) WAN  A 901 (-4.3A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.71A	37.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 9	TYR A 655 LEU A 770 LEU A 809 GLN A 859 PHE A 862	None	0.72A	21.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3thz	DNA MISMATCH REPAIR PROTEIN MSH2 (Homo sapiens)	5 / 9	LEU A 372 LEU A 432 VAL A 605 ALA A 604 LEU A 381	None	1.10A	17.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	TYR A 524 LEU A 635 LEU A 675 GLN A 726 PHE A 729	C1L  A   1 ( 4.8A) None C1L  A   1 (-4.3A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A)	0.58A	38.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3wv6	GALECTIN-9 (Homo sapiens)	5 / 9	LEU A 203 LEU A 226 VAL A 287 ALA A 288 LEU A  11	None	1.09A	23.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 9	TYR A 655 LEU A 770 LEU A 809 GLN A 859 PHE A 862	None	0.53A	34.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4kt1	LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR 4 (Homo sapiens)	5 / 9	LEU A 232 LEU A 216 VAL A 168 LEU A 182 PHE A 221	None	1.14A	23.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4mqj	HEMOGLOBIN SUBUNIT GAMMA-2 (Homo sapiens)	5 / 9	LEU B  68 LEU B 110 VAL B 137 ALA B 140 LEU B  88	None None None None HEM  B 201 (-4.6A)	1.27A	18.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4ono	BETA-2-MICROGLOBULIN /T-CELL SURFACE GLYCOPROTEIN CD1C/T-CELL SURFACE GLYCOPROTEIN CD1B CHIMERIC PROTEIN (Homo sapiens)	5 / 9	LEU A 178 VAL A 127 ALA A 215 LEU A 277 PHE A 285	None PMK  A 401 (-3.0A) PMK  A 401 (-2.7A) PMK  A 401 ( 3.8A) PMK  A 401 ( 3.6A)	1.25A	20.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4qxe	LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR 4, LINKER, VARIABLE LYMPHOCYTE RECEPTOR B (Eptatretus burgeri; Homo sapiens)	5 / 9	LEU A 232 LEU A 216 VAL A 168 LEU A 182 PHE A 221	None	1.13A	24.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4qxf	LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR 4, VARIABLE LYMPHOCYTE RECEPTOR B (Eptatretus burgeri; Homo sapiens)	5 / 9	LEU A 232 LEU A 216 VAL A 168 LEU A 182 PHE A 221	None	1.21A	24.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4ufs	LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR 5 (Homo sapiens)	5 / 9	LEU A 381 LEU A 367 VAL A 347 LEU A 354 PHE A 370	None	1.18A	23.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5mfa	MYELOPEROXIDASE (Homo sapiens)	5 / 9	TYR A 500 LEU A 263 LEU A 259 ALA A 662 PHE A 669	HEM  A 812 ( 4.3A) None None None None	1.24A	19.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5vhf	26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 3 (Homo sapiens)	5 / 9	LEU V 394 LEU V 338 VAL V 367 ALA V 366 LEU V 379	None	1.20A	20.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1m39	CALTRACTIN, ISOFORM 1 (Homo sapiens)	5 / 12	ILE A 121 VAL A 129 ALA A 130 MET A 145 PHE A  86	None	1.32A	16.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	6 / 12	TYR A 211 HIS A 212 VAL A 380 LEU A 401 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None IBM  A 503 (-4.7A) None IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.79A	28.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2hau	SEROTRANSFERRIN (Homo sapiens)	5 / 12	ASN A 268 ALA A  59 VAL A  81 ALA A  82 PHE A 295	None	1.33A	18.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	9 / 12	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 ALA A 783 MET A 816 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) VDN  A   1 ( 3.8A) VDN  A   1 (-4.5A) VDN  A   1 ( 4.7A) VDN  A   1 ( 4.0A) VDN  A   1 (-4.0A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.36A	100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 ALA A 783 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) WAN  A 901 ( 3.9A) WAN  A 901 ( 4.9A) WAN  A 901 ( 4.9A) WAN  A 901 (-3.6A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.34A	100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 MET A 816 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) WAN  A 901 ( 3.9A) WAN  A 901 ( 4.9A) WAN  A 901 ( 4.9A) WAN  A 901 (-4.3A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.61A	100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ecn	HIGH AFFINITY CAMP-SPECIFIC AND IBMX-INSENSITIVE 3',5'-CYCLIC PHOSPHODIESTERASE 8A (Homo sapiens)	5 / 12	TYR A 555 HIS A 556 ALA A 742 GLN A 778 PHE A 781	None None None IBM  A   3 (-3.4A) IBM  A   3 (-3.5A)	1.25A	26.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4awn	DEOXYRIBONUCLEASE-1 (Homo sapiens)	5 / 12	TYR A 151 ALA A 230 ILE A 214 VAL A 225 ALA A 224	None	1.17A	21.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4ifp	MALTOSE-BINDING PERIPLASMIC PROTEIN,NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 1 (Escherichia coli; Homo sapiens)	5 / 12	HIS A 445 ILE A 383 VAL A 389 LEU A 396 PHE A 423	MLI  A 502 (-4.1A) None None None None	1.32A	20.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5cmn	LATROPHILIN-3 (Homo sapiens)	5 / 12	TYR E 143 ALA E 366 ILE E 364 LEU E 139 PHE E 357	None	1.26A	18.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	1jv1	GLCNAC1P URIDYLTRANSFERASE ISOFORM 1: AGX1 (Homo sapiens)	5 / 12	LEU A 106 SER A 173 MET A 171 GLN A 233 PHE A 194	None	1.48A	21.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	7 / 12	TYR A 736 HIS A 737 ASP A 937 PHE A 959 GLN A 988 PHE A 991 ILE A 995	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) MG  A2123 (-2.5A) None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A) None	0.52A	30.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	6 / 12	TYR A 736 HIS A 737 ASP A 937 PHE A 959 SER A 974 GLN A 988	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) MG  A2123 (-2.5A) None None IBM  A2111 (-3.3A)	1.00A	30.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	5 / 12	TYR A 736 HIS A 741 GLN A 988 PHE A 991 ILE A 995	IBM  A2111 (-4.5A) MG  A2123 (-3.0A) IBM  A2111 (-3.3A) IBM  A2111 (-3.6A) None	1.48A	30.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	1zbu	3'-5' EXONUCLEASE ERI1 (Homo sapiens)	5 / 12	MET A 235 LEU A 227 MET A 344 SER A 246 ILE A 133	None	1.17A	19.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	6 / 12	TYR A 211 HIS A 212 ASP A 362 PHE A 384 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None ZN  A 501 (-2.5A) IBM  A 503 (-4.5A) IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.47A	34.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	1zli	CARBOXYPEPTIDASE B (Homo sapiens)	5 / 12	TYR A 192 LEU A 108 PHE A 147 SER A 172 ILE A  47	None	1.38A	19.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2d9j	REGULATOR OF G-PROTEIN SIGNALLING 7 (Homo sapiens)	5 / 12	LEU A  74 SER A 119 MET A 115 GLN A 108 PHE A  47	None	1.47A	17.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2pvs	PANCREATIC LIPASE-RELATED PROTEIN 2 (Homo sapiens)	5 / 12	LEU A 346 SER A 367 GLN A 445 PHE A 401 ILE A 356	None	1.50A	20.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 MET A 549 PHE A 552 MET A 569 GLN A 581 PHE A 584 ILE A 588	NPV  A   3 (-4.4A) NPV  A   3 (-4.6A) None ZN  A   1 (-2.5A) None NPV  A   3 ( 4.7A) NPV  A   3 (-4.8A) NPV  A   3 (-3.1A) NPV  A   3 (-3.1A) NPV  A   3 (-3.3A) None	0.42A	87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	7 / 12	TYR A 371 HIS A 376 MET A 485 LEU A 531 GLN A 581 PHE A 584 ILE A 588	NPV  A   3 (-4.4A) ZN  A   1 (-3.3A) None None NPV  A   3 (-3.1A) NPV  A   3 (-3.3A) None	1.49A	87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	8 / 12	TYR A 371 MET A 485 ASP A 530 LEU A 531 MET A 549 PHE A 552 SER A 567 PHE A 584	NPV  A   3 (-4.4A) None ZN  A   1 (-2.5A) None NPV  A   3 ( 4.7A) NPV  A   3 (-4.8A) None NPV  A   3 (-3.3A)	1.15A	87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qym	PHOSPHODIESTERASE 4C (Homo sapiens)	7 / 12	TYR A 281 HIS A 282 MET A 395 ASP A 440 LEU A 441 PHE A 494 ILE A 498	None None None ZN  A   1 (-2.5A) None None None	0.52A	75.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3aqg	ZYMOGEN GRANULE PROTEIN 16 HOMOLOG B (Homo sapiens)	5 / 12	LEU A 113 MET A 133 PHE A 145 SER A  88 ILE A  74	None	1.40A	17.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 GLN A 775	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) None VDN  A   1 ( 4.7A) VDN  A   1 ( 4.4A)	0.94A	28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 786 GLN A 817 PHE A 820 ILE A 824	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) None VDN  A   1 ( 4.7A) None VDN  A   1 (-3.0A) VDN  A   1 (-3.6A) None	0.65A	28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 GLN A 775	None MG  A 877 (-4.4A) ZN  A 876 (-2.5A) WAN  A 901 ( 4.7A) WAN  A 901 ( 4.6A)	0.84A	17.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 786 GLN A 817 PHE A 820 ILE A 824	None MG  A 877 (-4.4A) ZN  A 876 (-2.5A) WAN  A 901 ( 4.7A) WAN  A 901 (-4.8A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A) None	0.57A	17.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 617 GLN A 817 PHE A 820 ILE A 824	None ZN  A 876 (-3.3A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A) None	1.33A	17.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ecn	HIGH AFFINITY CAMP-SPECIFIC AND IBMX-INSENSITIVE 3',5'-CYCLIC PHOSPHODIESTERASE 8A (Homo sapiens)	6 / 12	TYR A 555 HIS A 556 MET A 670 ASP A 726 GLN A 778 PHE A 781	None None IBM  A   3 (-4.5A) ZN  A   1 (-2.6A) IBM  A   3 (-3.4A) IBM  A   3 (-3.5A)	0.44A	34.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 12	HIS A 330 MET A 439 LEU A 485 GLN A 535 PHE A 538	ZN  A 801 (-3.4A) D71  A 901 ( 4.0A) None D71  A 901 (-3.1A) D71  A 901 (-3.9A)	1.13A	66.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	6 / 12	MET A 439 LEU A 485 MET A 503 PHE A 506 GLN A 535 PHE A 538	D71  A 901 ( 4.0A) None D71  A 901 (-3.6A) D71  A 901 (-4.8A) D71  A 901 (-3.1A) D71  A 901 (-3.9A)	0.85A	66.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	9 / 12	TYR A 325 HIS A 326 ASP A 484 LEU A 485 MET A 503 PHE A 506 GLN A 535 PHE A 538 ILE A 542	None D71  A 901 (-4.5A) ZN  A 801 (-2.6A) None D71  A 901 (-3.6A) D71  A 901 (-4.8A) D71  A 901 (-3.1A) D71  A 901 (-3.9A) None	0.52A	66.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	6 / 12	TYR A 325 HIS A 326 ASP A 484 MET A 503 PHE A 506 SER A 521	None D71  A 901 (-4.5A) ZN  A 801 (-2.6A) D71  A 901 (-3.6A) D71  A 901 (-4.8A) None	1.02A	66.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	6 / 12	TYR A 325 HIS A 326 MET A 503 PHE A 506 MET A 523 GLN A 535	None D71  A 901 (-4.5A) D71  A 901 (-3.6A) D71  A 901 (-4.8A) D71  A 901 ( 4.0A) D71  A 901 (-3.1A)	0.77A	66.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 655 HIS A 656 ASP A 808 GLN A 859 PHE A 862 ILE A 866	None None ZN  A   1 (-2.7A) None None None	0.54A	19.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 PHE A 862 ILE A 866	None None ZN  A   1 (-2.7A) None None None	0.74A	19.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 HIS A 660 GLN A 859 PHE A 862 ILE A 866	None ZN  A   1 (-3.4A) None None None	1.49A	19.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ihp	UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 5 (Homo sapiens)	5 / 12	HIS A 236 LEU A 210 GLN A 185 PHE A 279 ILE A 192	None	1.48A	20.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ltl	BREFELDIN A-INHIBITED GUANINE NUCLEOTIDE-EXCHANGE PROTEIN 1 (Homo sapiens)	5 / 12	HIS A 770 MET A 801 LEU A 781 PHE A 788 ILE A 832	CA  A   2 (-4.0A) None None None None	1.16A	20.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3n3z	HIGH AFFINITY CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 9A (Homo sapiens)	5 / 12	HIS A 252 MET A 365 ASP A 402 GLN A 453 PHE A 456	None None ZN  A 507 (-2.9A) IBM  A   1 (-3.5A) IBM  A   1 (-3.4A)	0.51A	30.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 MET A 411 PHE A 414 GLN A 443 PHE A 446 ILE A 450	None None ZG2  A 506 (-3.9A) ZN  A   1 (-2.6A) None None ZG2  A 506 (-4.4A) ZG2  A 506 (-3.3A) ZG2  A 506 (-3.6A) None	0.52A	93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 MET A 411 PHE A 414 MET A 431 GLN A 443 PHE A 446	None None ZG2  A 506 (-3.9A) ZN  A   1 (-2.6A) None None ZG2  A 506 (-4.4A) ZG2  A 506 (-3.4A) ZG2  A 506 (-3.3A) ZG2  A 506 (-3.6A)	0.57A	93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	9 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 MET A 411 PHE A 414 SER A 429 GLN A 443 PHE A 446	None None ZG2  A 506 (-3.9A) ZN  A   1 (-2.6A) None ZG2  A 506 (-4.4A) ARS  A   3 (-4.4A) ZG2  A 506 (-3.3A) ZG2  A 506 (-3.6A)	0.91A	93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	11 / 12	TYR A 159 HIS A 160 MET A 273 ASP A 318 LEU A 319 MET A 337 PHE A 340 MET A 357 GLN A 369 PHE A 372 ILE A 376	TYR  A 159 (-1.3A) HIS  A 160 ( 1.0A) MET  A 273 (-0.0A) ASP  A 318 (-0.5A) LEU  A 319 ( 0.6A) MET  A 337 ( 0.0A) PHE  A 340 (-1.3A) MET  A 357 (-0.0A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A) ILE  A 376 (-0.6A)	0.48A	84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	10 / 12	TYR A 159 HIS A 160 MET A 273 ASP A 318 LEU A 319 MET A 337 PHE A 340 SER A 355 GLN A 369 PHE A 372	TYR  A 159 (-1.3A) HIS  A 160 ( 1.0A) MET  A 273 (-0.0A) ASP  A 318 (-0.5A) LEU  A 319 ( 0.6A) MET  A 337 ( 0.0A) PHE  A 340 (-1.3A) SER  A 355 ( 0.0A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A)	1.02A	84.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 ASP A 674 LEU A 675 MET A 713 GLN A 726 PHE A 729	C1L  A   1 ( 4.8A) ZN  A 772 (-2.4A) C1L  A   1 (-4.3A) C1L  A   1 (-3.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A)	1.19A	27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L  A   1 ( 4.8A) C1L  A   1 (-4.1A) ZN  A 772 (-2.4A) C1L  A   1 (-4.3A) C1L  A   1 ( 4.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A)	0.70A	27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 ASP A 808 LEU A 809 MET A 847 GLN A 859 PHE A 862 ILE A 866	None ZN  A1001 (-2.5A) None None None None None	0.90A	27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 PHE A 830 GLN A 859 PHE A 862 ILE A 866	None None ZN  A1001 (-2.5A) None None None None None	0.60A	27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 HIS A 660 GLN A 859 PHE A 862 ILE A 866	None ZN  A1001 (-3.4A) None None None	1.38A	27.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	9 / 12	TYR A 405 HIS A 406 ASP A 564 LEU A 565 MET A 583 PHE A 586 GLN A 615 PHE A 618 ILE A 622	None MG  A 804 ( 4.9A) ZN  A 801 (-2.5A) None None None None None None	0.56A	61.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 12	TYR A 405 HIS A 406 ASP A 564 MET A 583 PHE A 586 SER A 601 GLN A 615	None MG  A 804 ( 4.9A) ZN  A 801 (-2.5A) None None None None	1.10A	61.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 12	TYR A 405 HIS A 406 MET A 583 PHE A 586 MET A 603 GLN A 615	None MG  A 804 ( 4.9A) None None None None	0.84A	61.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 12	TYR A 405 HIS A 410 LEU A 565 GLN A 615 PHE A 618 ILE A 622	None ZN  A 801 (-3.2A) None None None None	1.45A	61.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	8 / 12	TYR A 405 MET A 519 ASP A 564 LEU A 565 MET A 583 PHE A 586 GLN A 615 PHE A 618	None None ZN  A 801 (-2.5A) None None None None None	0.80A	61.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 12	TYR A 405 MET A 519 ASP A 564 MET A 583 PHE A 586 SER A 601 GLN A 615	None None ZN  A 801 (-2.5A) None None None None	1.22A	61.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PHE A 392 GLN A 421 PHE A 424 ILE A 428	None 4QJ  A 603 ( 4.9A) 4QJ  A 603 ( 3.9A) ZN  A 601 (-2.5A) GOL  A 607 (-3.9A) 4QJ  A 603 (-3.0A) 4QJ  A 603 (-3.5A) None	0.66A	35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	6 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PHE A 392 SER A 407	None 4QJ  A 603 ( 4.9A) 4QJ  A 603 ( 3.9A) ZN  A 601 (-2.5A) GOL  A 607 (-3.9A) GOL  A 607 (-4.1A)	1.12A	35.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 405 HIS A 406 MET A 519 ASP A 564 LEU A 565 MET A 583 PHE A 586 MET A 603 GLN A 615 PHE A 618 ILE A 622	None None 9VE  A 801 (-3.8A) ZN  A 699 ( 2.6A) 9VE  A 801 (-4.7A) 9VE  A 801 ( 4.0A) 9VE  A 801 (-3.6A) 9VE  A 801 (-3.6A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A) 9VE  A 801 (-4.8A)	0.61A	11.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 12	TYR A 405 HIS A 406 MET A 519 ASP A 564 MET A 583 PHE A 586 SER A 601	None None 9VE  A 801 (-3.8A) ZN  A 699 ( 2.6A) 9VE  A 801 ( 4.0A) 9VE  A 801 (-3.6A) None	1.21A	11.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 12	TYR A 405 HIS A 410 MET A 519 LEU A 565 GLN A 615 PHE A 618 ILE A 622	None ZN  A 699 (-3.3A) 9VE  A 801 (-3.8A) 9VE  A 801 (-4.7A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A) 9VE  A 801 (-4.8A)	1.46A	11.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	11 / 12	TYR A 159 HIS A 160 MET A 273 ASP A 318 LEU A 319 MET A 337 PHE A 340 MET A 357 GLN A 369 PHE A 372 ILE A 376	AKJ  A 601 ( 4.7A) None AKJ  A 601 ( 3.9A) ZN  A 602 (-2.5A) AKJ  A 601 ( 4.6A) AKJ  A 601 ( 3.7A) AKJ  A 601 (-4.5A) AKJ  A 601 (-3.4A) AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A) None	0.52A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	9 / 12	TYR A 159 HIS A 160 MET A 273 ASP A 318 MET A 337 PHE A 340 SER A 355 GLN A 369 PHE A 372	AKJ  A 601 ( 4.7A) None AKJ  A 601 ( 3.9A) ZN  A 602 (-2.5A) AKJ  A 601 ( 3.7A) AKJ  A 601 (-4.5A) None AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A)	1.04A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1nf1	PROTEIN (NEUROFIBROMIN) (Homo sapiens)	5 / 11	ALA A1429 ILE A1428 LEU A1300 ILE A1397 PHE A1347	None	1.06A	24.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	5 / 11	TYR A 736 HIS A 737 PHE A 959 GLN A 988 PHE A 991	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A)	0.37A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1vzo	RIBOSOMAL PROTEIN S6 KINASE ALPHA 5 (Homo sapiens)	5 / 11	ALA A 286 ILE A 290 VAL A 154 LEU A 139 ILE A 161	None	1.18A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1wz9	MASPIN PRECURSOR (Homo sapiens)	5 / 11	ALA A  51 ILE A  54 PHE A 104 LEU A 116 ILE A 159	None	1.12A	20.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	7 / 11	TYR A 211 HIS A 212 VAL A 380 PHE A 384 ILE A 409 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None IBM  A 503 (-4.7A) IBM  A 503 (-4.5A) None IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.66A	28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	7 / 11	TYR A 211 HIS A 212 VAL A 380 PHE A 384 LEU A 401 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None IBM  A 503 (-4.7A) IBM  A 503 (-4.5A) None IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.81A	28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2h63	BILIVERDIN REDUCTASE A (Homo sapiens)	5 / 11	TYR A  98 ILE A 250 LEU A  95 ILE A 257 PHE A 251	NAP  A 501 (-3.6A) None None None None	1.22A	20.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	TYR A 371 HIS A 372 PHE A 552 GLN A 581 PHE A 584	NPV  A   3 (-4.4A) NPV  A   3 (-4.6A) NPV  A   3 (-4.8A) NPV  A   3 (-3.1A) NPV  A   3 (-3.3A)	0.44A	29.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	9 / 11	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 PHE A 786 ILE A 813 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) VDN  A   1 ( 3.8A) VDN  A   1 (-4.5A) VDN  A   1 ( 4.7A) None VDN  A   1 ( 4.2A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.47A	100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	9 / 11	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 PHE A 786 ILE A 813 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) WAN  A 901 ( 3.9A) WAN  A 901 ( 4.9A) WAN  A 901 ( 4.9A) WAN  A 901 (-4.8A) WAN  A 901 ( 4.3A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.35A	100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ecn	HIGH AFFINITY CAMP-SPECIFIC AND IBMX-INSENSITIVE 3',5'-CYCLIC PHOSPHODIESTERASE 8A (Homo sapiens)	5 / 11	TYR A 555 HIS A 556 ILE A 774 GLN A 778 PHE A 781	None None None IBM  A   3 (-3.4A) IBM  A   3 (-3.5A)	0.37A	25.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 11	TYR A 325 HIS A 326 PHE A 506 GLN A 535 PHE A 538	None D71  A 901 (-4.5A) D71  A 901 (-4.8A) D71  A 901 (-3.1A) D71  A 901 (-3.9A)	0.56A	26.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	TYR A 655 HIS A 656 ILE A 855 GLN A 859 PHE A 862	None	0.61A	21.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3n93	MALTOSE BINDING PROTEIN-CRFR2 ALPHA (Homo sapiens)	5 / 11	ALA A -67 ILE A-262 VAL A-273 LEU A-294 ILE A-291	None	1.26A	19.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3n94	FUSION PROTEIN OF MALTOSE-BINDING PERIPLASMIC PROTEIN AND PITUITARY ADENYLATE CYCLASE 1 RECEPTOR-SHORT (Escherichia coli; Homo sapiens)	5 / 11	ALA A -45 ILE A-240 VAL A-251 LEU A-272 ILE A-269	None	1.25A	20.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 PHE A 414 GLN A 443 PHE A 446	None None ZG2  A 506 (-4.4A) ZG2  A 506 (-3.3A) ZG2  A 506 (-3.6A)	0.59A	27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 11	TYR A 159 HIS A 160 PHE A 340 GLN A 369 PHE A 372	TYR  A 159 (-1.3A) HIS  A 160 ( 1.0A) PHE  A 340 (-1.3A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A)	0.50A	29.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 11	TYR A 524 HIS A 525 PHE A 696 GLN A 726 PHE A 729	C1L  A   1 ( 4.8A) C1L  A   1 (-4.1A) C1L  A   1 ( 4.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A)	0.47A	39.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4giz	MALTOSE-BINDING PERIPLASMIC PROTEIN, UBIQUITIN LIGASE EA6P: CHIMERIC PROTEIN (Escherichia coli; Homo sapiens)	5 / 11	ALA A 304 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	1.23A	21.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 11	TYR A 655 HIS A 656 PHE A 830 ILE A 855 GLN A 859 PHE A 862	None	0.45A	35.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4ikm	MALTOSE-BINDING PERIPLASMIC PROTEIN, CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 8 (Escherichia coli; Homo sapiens)	5 / 11	ALA A 304 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	1.23A	21.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4keg	MALTOSE-BINDING PERIPLASMIC/PALATE LUNG AND NASAL EPITHELIUM CLONE FUSION PROTEIN (Escherichia coli; Homo sapiens)	5 / 11	ALA A 303 ILE A 108 VAL A  97 LEU A  76 ILE A  79	None	1.21A	20.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4log	MALTOSE ABC TRANSPORTER PERIPLASMIC PROTEIN AND NR2E3 PROTEIN CHIMERIC CONSTRUCT (Escherichia coli; Homo sapiens)	5 / 11	ALA A 305 ILE A 110 VAL A  99 LEU A  78 ILE A  81	None	1.13A	20.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4my2	MALTOSE-BINDING PERIPLASMIC PROTEIN, NORRIN FUSION PROTEIN (Escherichia coli; Homo sapiens)	5 / 11	ALA A 305 ILE A 110 VAL A  99 LEU A  78 ILE A  81	None	1.23A	19.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 405 HIS A 406 PHE A 586 GLN A 615 PHE A 618	None MG  A 804 ( 4.9A) None None None	0.32A	21.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5a1k	ADSEVERIN (Homo sapiens)	5 / 11	ASN A 270 ALA A 241 PHE A 343 LEU A 285 GLN A 292	None	1.14A	23.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 11	TYR A 222 HIS A 223 PHE A 392 GLN A 421 PHE A 424	None 4QJ  A 603 ( 4.9A) GOL  A 607 (-3.9A) 4QJ  A 603 (-3.0A) 4QJ  A 603 (-3.5A)	0.63A	28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5h7n	NLRP12-PYD WITH MBP TAG (Homo sapiens)	5 / 11	ALA A 304 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	1.26A	21.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5hzk	INTERSECTIN-1,NPH1-1 ,INTERSECTIN-1 (Avena sativa; Homo sapiens)	5 / 11	ASN B1397 ALA B1335 ILE B1350 PHE B1395 PHE B1357	FMN  B1801 (-4.2A) None None None None	1.16A	22.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5hzv	MALTOSE-BINDING PERIPLASMIC PROTEIN,ENDOGLIN (Escherichia coli; Homo sapiens)	5 / 11	ALA A 670 ILE A 475 VAL A 464 LEU A 443 ILE A 446	None	1.26A	20.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 405 HIS A 406 PHE A 586 GLN A 615 PHE A 618	None None 9VE  A 801 (-3.6A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A)	0.37A	13.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5tj7	NEDD4-LIKE E3 UBIQUITIN-PROTEIN LIGASE WWP2 (Homo sapiens)	5 / 11	ILE A 755 VAL A 783 PHE A 779 LEU A 842 ILE A 861	None	1.19A	23.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5v6y	MALTOSE-BINDING PERIPLASMIC PROTEIN,RECEPTOR ACTIVITY-MODIFYING PROTEIN 1,CALCITONIN GENE-RELATED PEPTIDE TYPE 1 RECEPTOR (Escherichia coli; Homo sapiens)	5 / 11	ALA A 305 ILE A 110 VAL A  99 LEU A  78 ILE A  81	None	1.25A	13.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 11	TYR A 159 HIS A 160 PHE A 340 GLN A 369 PHE A 372	AKJ  A 601 ( 4.7A) None AKJ  A 601 (-4.5A) AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A)	0.37A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	6d7t	TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY V MEMBER 6 (Homo sapiens)	5 / 11	ASN A 464 ILE A 420 ILE A 480 GLN A 483 PHE A 487	None	1.23A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1nf1	PROTEIN (NEUROFIBROMIN) (Homo sapiens)	5 / 12	ALA A1429 ILE A1428 LEU A1300 ILE A1397 PHE A1347	None	1.05A	24.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1vzo	RIBOSOMAL PROTEIN S6 KINASE ALPHA 5 (Homo sapiens)	5 / 12	ALA A 286 ILE A 290 VAL A 154 LEU A 139 ILE A 161	None	1.08A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	6 / 12	TYR A 211 HIS A 212 VAL A 380 ILE A 409 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None IBM  A 503 (-4.7A) None IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.68A	28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	5 / 12	TYR A 211 HIS A 212 VAL A 380 LEU A 401 GLN A 413	IBM  A 503 (-4.6A) None IBM  A 503 (-4.7A) None IBM  A 503 (-3.0A)	0.92A	28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2div	TRNA SELENOCYSTEINE ASSOCIATED PROTEIN (Homo sapiens)	5 / 12	ASN A  89 ALA A  52 ILE A  43 ILE A  26 PHE A  56	None	1.06A	15.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	10 / 12	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 ALA A 783 ILE A 813 MET A 816 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) VDN  A   1 ( 3.8A) VDN  A   1 (-4.5A) VDN  A   1 ( 4.7A) VDN  A   1 ( 4.0A) VDN  A   1 ( 4.2A) VDN  A   1 (-4.0A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.36A	100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	10 / 12	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 ALA A 783 ILE A 813 MET A 816 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) WAN  A 901 ( 3.9A) WAN  A 901 ( 4.9A) WAN  A 901 ( 4.9A) WAN  A 901 (-3.6A) WAN  A 901 ( 4.3A) WAN  A 901 (-4.3A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.47A	100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ecn	HIGH AFFINITY CAMP-SPECIFIC AND IBMX-INSENSITIVE 3',5'-CYCLIC PHOSPHODIESTERASE 8A (Homo sapiens)	5 / 12	TYR A 555 HIS A 556 ILE A 774 GLN A 778 PHE A 781	None None None IBM  A   3 (-3.4A) IBM  A   3 (-3.5A)	0.46A	25.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 HIS A 656 ILE A 855 GLN A 859 PHE A 862	None	0.58A	21.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3nuu	PKB-LIKE (Homo sapiens)	5 / 12	ILE A 272 VAL A 190 ALA A 192 LEU A 350 ILE A 219	None None None GOL  A 365 (-3.9A) None	1.11A	20.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 HIS A 656 ILE A 855 GLN A 859 PHE A 862	None	0.42A	35.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5aga	DNA POLYMERASE THETA (Homo sapiens)	5 / 12	TYR A 239 ALA A 544 ILE A 539 ALA A 554 LEU A 519	None	1.03A	17.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5vhf	26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 3 (Homo sapiens)	5 / 12	HIS V 453 ALA V 434 ILE V 437 ALA V 449 ILE V 447	None	1.14A	21.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	6d7t	TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY V MEMBER 6 (Homo sapiens)	5 / 12	ASN A 464 ILE A 420 ILE A 480 GLN A 483 PHE A 487	None	1.15A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	5 / 12	TYR A 736 LEU A 895 PHE A 959 GLN A 988 PHE A 991	IBM  A2111 (-4.5A) None None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A)	0.41A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	5 / 12	TYR A 211 VAL A 380 ILE A 409 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) IBM  A 503 (-4.7A) None IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.72A	28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	5 / 12	TYR A 211 VAL A 380 PHE A 384 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) IBM  A 503 (-4.7A) IBM  A 503 (-4.5A) IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.54A	28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	TYR A 371 LEU A 531 PHE A 552 GLN A 581 PHE A 584	NPV  A   3 (-4.4A) None NPV  A   3 (-4.8A) NPV  A   3 (-3.1A) NPV  A   3 (-3.3A)	0.42A	29.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2yd3	RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE S (Homo sapiens)	5 / 12	LEU A  96 LEU A 122 ALA A 213 PHE A 134 LEU A 130	None	1.00A	22.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	11 / 12	TYR A 612 LEU A 725 LEU A 765 ALA A 767 ILE A 768 VAL A 782 ALA A 783 PHE A 786 ILE A 813 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) None VDN  A   1 ( 4.7A) VDN  A   1 ( 3.8A) VDN  A   1 (-4.5A) VDN  A   1 ( 4.7A) VDN  A   1 ( 4.0A) None VDN  A   1 ( 4.2A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.41A	100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	11 / 12	TYR A 612 LEU A 725 LEU A 765 ALA A 767 ILE A 768 VAL A 782 ALA A 783 PHE A 786 ILE A 813 GLN A 817 PHE A 820	None None WAN  A 901 ( 4.7A) WAN  A 901 ( 3.9A) WAN  A 901 ( 4.9A) WAN  A 901 ( 4.9A) WAN  A 901 (-3.6A) WAN  A 901 (-4.8A) WAN  A 901 ( 4.3A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.31A	100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 12	TYR A 325 LEU A 485 PHE A 506 GLN A 535 PHE A 538	None None D71  A 901 (-4.8A) D71  A 901 (-3.1A) D71  A 901 (-3.9A)	0.60A	26.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 LEU A 770 LEU A 809 ILE A 855 PHE A 862	None	0.58A	21.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3n93	MALTOSE BINDING PROTEIN-CRFR2 ALPHA (Homo sapiens)	5 / 12	LEU A-108 ILE A-262 VAL A-273 LEU A-294 ILE A-291	None	0.95A	19.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3n94	FUSION PROTEIN OF MALTOSE-BINDING PERIPLASMIC PROTEIN AND PITUITARY ADENYLATE CYCLASE 1 RECEPTOR-SHORT (Escherichia coli; Homo sapiens)	5 / 12	LEU A -86 ILE A-240 VAL A-251 LEU A-272 ILE A-269	None	0.92A	20.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	TYR A 233 LEU A 393 PHE A 414 GLN A 443 PHE A 446	None None ZG2  A 506 (-4.4A) ZG2  A 506 (-3.3A) ZG2  A 506 (-3.6A)	0.60A	27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3oai	MALTOSE-BINDING PERIPLASMIC PROTEIN, MYELIN PROTEIN P0 (Escherichia coli; Homo sapiens)	5 / 12	LEU A 262 ILE A 108 VAL A  97 LEU A  76 ILE A  79	None	1.07A	19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3py7	MALTOSE-BINDING PERIPLASMIC PROTEIN,PAXILLIN LD1,PROTEIN E6 CHIMERA (Deltapapillomavi rus 4; Escherichia coli; Homo sapiens)	5 / 12	LEU A 263 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	1.07A	21.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 12	TYR A 159 LEU A 319 PHE A 340 GLN A 369 PHE A 372	TYR  A 159 (-1.3A) LEU  A 319 ( 0.6A) PHE  A 340 (-1.3A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A)	0.43A	29.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 635 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L  A   1 ( 4.8A) None C1L  A   1 (-4.3A) C1L  A   1 ( 4.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A)	0.47A	39.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3vd8	MALTOSE-BINDING PERIPLASMIC PROTEIN, INTERFERON-INDUCIBLE PROTEIN AIM2 (Escherichia coli; Homo sapiens)	5 / 12	LEU A 262 ILE A 108 VAL A  97 LEU A  76 ILE A  79	None	0.96A	21.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4egc	MALTOSE-BINDING PERIPLASMIC PROTEIN, HOMEOBOX PROTEIN SIX1 CHIMERA (Escherichia coli; Homo sapiens)	5 / 12	LEU A 262 ILE A 108 VAL A  97 LEU A  76 ILE A  79	None	0.99A	21.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4f92	U5 SMALL NUCLEAR RIBONUCLEOPROTEIN 200 KDA HELICASE (Homo sapiens)	5 / 12	LEU B1320 LEU B1365 ALA B1363 ILE B1426 PHE B1397	None	0.85A	11.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4giz	MALTOSE-BINDING PERIPLASMIC PROTEIN, UBIQUITIN LIGASE EA6P: CHIMERIC PROTEIN (Escherichia coli; Homo sapiens)	5 / 12	LEU A 263 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	0.97A	21.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4hsu	LYSINE-SPECIFIC HISTONE DEMETHYLASE 1B (Homo sapiens)	5 / 12	LEU A 632 ILE A 786 VAL A 623 ILE A 819 PHE A 792	None	1.13A	18.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 LEU A 770 LEU A 809 PHE A 830 ILE A 855 GLN A 859 PHE A 862	None	0.57A	35.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4ikm	MALTOSE-BINDING PERIPLASMIC PROTEIN, CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 8 (Escherichia coli; Homo sapiens)	5 / 12	LEU A 263 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	0.94A	21.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4p5w	CALCIUM-BINDING MITOCHONDRIAL CARRIER PROTEIN ARALAR2,CALCIUM-BIND ING MITOCHONDRIAL CARRIER PROTEIN ARALAR2 (Homo sapiens)	5 / 12	LEU A 195 LEU A 203 ALA A 205 ALA A 276 PHE A 223	None	0.76A	22.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4rwf	MALTOSE TRANSPORTER SUBUNIT, RECEPTOR ACTIVITY-MODIFYING PROTEIN 2, CALCITONIN GENE-RELATED PEPTIDE TYPE 1 RECEPTOR FUSION PROTEIN (Escherichia coli; Homo sapiens)	5 / 12	LEU A 264 ILE A 110 VAL A  99 LEU A  78 ILE A  81	None	1.00A	20.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	TYR A 405 LEU A 565 PHE A 586 GLN A 615 PHE A 618	None	0.52A	21.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	5 / 12	LEU A 783 LEU A 788 ALA A 792 ILE A 881 VAL A 825	None	1.05A	21.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5h7n	NLRP12-PYD WITH MBP TAG (Homo sapiens)	5 / 12	LEU A 263 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	0.95A	21.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5jcp	ARF-GAP WITH RHO-GAP DOMAIN, ANK REPEAT AND PH DOMAIN-CONTAINING PROTEIN 3,LINKER,TRANSFORMIN G PROTEIN RHOA (Homo sapiens; synthetic construct)	5 / 12	LEU B 980 LEU B1034 ALA B1032 ILE B1035 LEU B 935	None	1.03A	22.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5jd0	ARF-GAP WITH RHO-GAP DOMAIN, ANK REPEAT AND PH DOMAIN-CONTAINING PROTEIN 3 (Homo sapiens)	5 / 12	LEU A 980 LEU A1034 ALA A1032 ILE A1035 LEU A 935	None	1.10A	19.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	TYR A 405 LEU A 565 PHE A 586 GLN A 615 PHE A 618	None 9VE  A 801 (-4.7A) 9VE  A 801 (-3.6A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A)	0.56A	13.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5ufl	PROTEIN CIP2A (Homo sapiens)	5 / 12	LEU A 288 LEU A 303 ALA A 305 VAL A 255 ILE A 238	None	1.01A	21.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 12	TYR A 159 LEU A 319 PHE A 340 GLN A 369 PHE A 372	AKJ  A 601 ( 4.7A) AKJ  A 601 ( 4.6A) AKJ  A 601 (-4.5A) AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A)	0.55A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5wq6	MBP TAGGED HMNDA-PYD (Homo sapiens)	5 / 12	LEU A 263 ILE A 109 VAL A  98 LEU A  77 ILE A  80	None	1.08A	20.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	1byw	PROTEIN (HUMAN ERG POTASSIUM CHANNEL) (Homo sapiens)	3 / 3	ASN A  45 ILE A  42 MET A 124	None	0.75A	13.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2i7t	CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 73 KDA SUBUNIT (Homo sapiens)	3 / 3	ASN A 450 ILE A  59 MET A  38	None	0.85A	20.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	ASN A 599 ILE A 596 MET A 622	None	0.81A	21.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3lmk	METABOTROPIC GLUTAMATE RECEPTOR 5 (Homo sapiens)	3 / 3	ASN A  88 ILE A  35 MET A 429	None	0.66A	19.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3vfd	SPASTIN (Homo sapiens)	3 / 3	ASN A 580 ILE A 562 MET A 573	None	0.76A	21.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4a69	HISTONE DEACETYLASE 3, (Homo sapiens)	3 / 3	ASN A 128 ILE A 125 MET A  45	None	0.79A	20.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4bla	MALTOSE-BINDING PERIPLASMIC PROTEIN, SUPPRESSOR OF FUSED HOMOLOG (Escherichia coli; Homo sapiens)	3 / 3	ASN A 639 ILE A 671 MET A 669	None	0.80A	18.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4ccz	METHIONINE SYNTHASE (Homo sapiens)	3 / 3	ASN A 539 ILE A 558 MET A 607	None	0.74A	20.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4elj	RETINOBLASTOMA-ASSOC IATED PROTEIN (Homo sapiens)	3 / 3	ASN A 519 ILE A 422 MET A 484	None	0.72A	19.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5bqd	T-BOX TRANSCRIPTION FACTOR TBX5 (Homo sapiens)	3 / 3	ASN A 230 ILE A 222 MET A  74	None	0.57A	20.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_2 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5hzh	RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1,NPH1-1,RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (Avena sativa; Homo sapiens)	3 / 3	ASN A 185 ILE A  64 MET A 146	None	0.85A	21.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	6 / 9	TYR A 736 HIS A 737 LEU A 895 LEU A 984 GLN A 988 PHE A 991	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) None None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A)	0.52A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1z8l	GLUTAMATE CARBOXYPEPTIDASE II (Homo sapiens)	5 / 9	TYR A 692 HIS A 689 LEU A 671 LEU A 632 PHE A 639	None	1.24A	18.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	6 / 9	TYR A 211 HIS A 212 VAL A 380 GLN A 413 PHE A 416 VAL A 421	IBM  A 503 (-4.6A) None IBM  A 503 (-4.7A) IBM  A 503 (-3.0A) IBM  A 503 (-3.4A) None	1.33A	27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2kzt	PROGRAMMED CELL DEATH PROTEIN 4 (Homo sapiens)	5 / 9	LEU A 223 VAL A 261 LEU A 295 PHE A 240 VAL A 236	None	1.49A	20.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 9	TYR A 371 HIS A 372 MET A 569 GLN A 581 PHE A 584	NPV  A   3 (-4.4A) NPV  A   3 (-4.6A) NPV  A   3 (-3.1A) NPV  A   3 (-3.1A) NPV  A   3 (-3.3A)	0.90A	29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2xst	LIPOCALIN 15 (Homo sapiens)	5 / 9	TYR A 139 LEU A 104 VAL A  39 PHE A  77 VAL A  86	None None EDO  A1174 ( 4.7A) EDO  A1174 (-4.6A) None	1.45A	19.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 9	TYR A 612 HIS A 613 LEU A 725 VAL A 782 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) None VDN  A   1 ( 4.7A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.42A	93.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 9	TYR A 612 HIS A 613 LEU A 725 VAL A 782 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) None WAN  A 901 ( 4.9A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.38A	35.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 9	TYR A 655 HIS A 656 LEU A 770 GLN A 859 PHE A 862	None	0.67A	21.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3jxf	RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE ZETA (Homo sapiens)	5 / 9	HIS A 129 LEU A 235 LEU A 106 PHE A 166 VAL A 170	None	1.41A	22.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 9	TYR A 159 HIS A 160 MET A 357 GLN A 369 PHE A 372	TYR  A 159 (-1.3A) HIS  A 160 ( 1.0A) MET  A 357 (-0.0A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A)	1.01A	28.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 9	TYR A 524 HIS A 525 LEU A 635 MET A 713 GLN A 726 PHE A 729 VAL A 733	C1L  A   1 ( 4.8A) C1L  A   1 (-4.1A) None C1L  A   1 (-3.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A) None	0.60A	42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 9	TYR A 655 HIS A 656 LEU A 770 MET A 847 GLN A 859 PHE A 862	None	0.39A	35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4qu7	G-RICH SEQUENCE FACTOR 1 (Homo sapiens)	5 / 9	LEU A 408 VAL A 403 LEU A 424 PHE A 420 VAL A 464	None	1.24A	13.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4rh7	GREEN FLUORESCENT PROTEIN/CYTOPLASMIC DYNEIN 2 HEAVY CHAIN 1 (Homo sapiens; synthetic construct)	5 / 9	TYR A1664 LEU A1613 GLN A1544 PHE A1547 VAL A1551	None	1.48A	7.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5eh1	INTERFERON GAMMA RECEPTOR 2 (Homo sapiens)	5 / 9	TYR A  69 VAL A 111 LEU A  40 GLN A  45 VAL A  84	None None None None GOL  A 306 (-4.2A)	1.20A	19.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 9	TYR A 405 HIS A 406 MET A 603 GLN A 615 PHE A 618	None None 9VE  A 801 (-3.6A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A)	0.63A	13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 9	TYR A 159 HIS A 160 MET A 357 GLN A 369 PHE A 372	AKJ  A 601 ( 4.7A) None AKJ  A 601 (-3.4A) AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A)	0.85A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1dk8	AXIN (Homo sapiens)	5 / 11	TYR A 185 LEU A 143 ALA A 157 VAL A 193 THR A 234	None	1.42A	21.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	6 / 11	TYR A 736 HIS A 737 LEU A 895 LEU A 984 GLN A 988 PHE A 991	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) None None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A)	0.66A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1z8l	GLUTAMATE CARBOXYPEPTIDASE II (Homo sapiens)	6 / 11	TYR A 692 HIS A 689 LEU A 671 LEU A 632 PHE A 639 THR A 745	None	1.47A	18.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	6 / 11	TYR A 211 HIS A 212 ASN A 260 VAL A 380 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None None IBM  A 503 (-4.7A) IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.82A	27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	TYR A 371 HIS A 372 MET A 569 GLN A 581 PHE A 584	NPV  A   3 (-4.4A) NPV  A   3 (-4.6A) NPV  A   3 (-3.1A) NPV  A   3 (-3.1A) NPV  A   3 (-3.3A)	0.75A	29.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 612 HIS A 613 LEU A 725 ALA A 767 VAL A 782 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) None VDN  A   1 ( 3.8A) VDN  A   1 ( 4.7A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.40A	93.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 11	TYR A 612 HIS A 613 ASN A 661 ALA A 767 VAL A 782 GLN A 817	None MG  A 877 (-4.4A) None WAN  A 901 ( 3.9A) WAN  A 901 ( 4.9A) WAN  A 901 (-3.1A)	1.39A	35.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 612 HIS A 613 LEU A 725 ALA A 767 VAL A 782 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) None WAN  A 901 ( 3.9A) WAN  A 901 ( 4.9A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.38A	35.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3fed	GLUTAMATE CARBOXYPEPTIDASE III (Homo sapiens)	5 / 11	HIS A 679 LEU A 661 ALA A 593 LEU A 622 PHE A 629	None	1.15A	17.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3fed	GLUTAMATE CARBOXYPEPTIDASE III (Homo sapiens)	5 / 11	HIS A 679 LEU A 661 ALA A 593 PHE A 629 THR A 735	None	1.24A	17.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	TYR A 655 HIS A 656 LEU A 770 GLN A 859 PHE A 862	None	0.68A	21.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 11	TYR A 159 HIS A 160 MET A 357 GLN A 369 PHE A 372	TYR  A 159 (-1.3A) HIS  A 160 ( 1.0A) MET  A 357 (-0.0A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A)	0.94A	28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3te7	RIBOSYLDIHYDRONICOTI NAMIDE DEHYDROGENASE [QUINONE] (Homo sapiens)	5 / 11	LEU A 120 ALA A  94 LEU A 184 PHE A 181 THR A 175	None	1.42A	22.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 11	TYR A 524 HIS A 525 LEU A 635 MET A 713 GLN A 726 PHE A 729	C1L  A   1 ( 4.8A) C1L  A   1 (-4.1A) None C1L  A   1 (-3.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A)	0.77A	42.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ulv	FAB12 HEAVY CHAIN (Homo sapiens)	5 / 11	TYR D 154 HIS D 209 LEU D 117 ALA D 177 THR D  94	None	1.21A	19.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4fze	N26_I1 FAB HEAVY CHAIN (Homo sapiens)	5 / 11	TYR H 145 HIS H 200 LEU H 108 ALA H 168 THR H  87	None	1.11A	19.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 655 HIS A 656 ASN A 704 LEU A 770 MET A 847 GLN A 859 PHE A 862	None	0.80A	35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4lly	MUTATED PERTUZUMAB FAB HEAVY CHAIN (Homo sapiens)	5 / 11	TYR A 151 HIS A 206 LEU A 114 ALA A 174 THR A  91	None	1.20A	19.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4qik	ROQUIN-1 (Homo sapiens)	5 / 11	ASN A 351 ALA A 291 LEU A 171 GLN A 174 THR A 344	None	1.48A	23.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4yhp	FAB HEAVY CHAIN (Homo sapiens)	5 / 11	TYR A 153 HIS A 208 LEU A 116 ALA A 176 THR A  91	None	1.29A	18.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5dur	HEAVY CHAIN OF ANTIBODY 100F4 (Homo sapiens)	5 / 11	TYR H 153 HIS H 208 LEU H 116 ALA H 176 THR H  92	None	1.21A	18.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 405 HIS A 406 MET A 603 GLN A 615 PHE A 618	None None 9VE  A 801 (-3.6A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A)	0.59A	13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5tqa	DH270.6 FAB HEAVY CHAIN (Homo sapiens)	5 / 11	TYR H 159 HIS H 214 LEU H 122 ALA H 182 THR H  91	None	1.17A	18.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5ubz	ANTI-HIV1 GP120 MAB 1E12 FAB HEAVY CHAIN (Homo sapiens)	5 / 11	TYR H 144 HIS H 199 LEU H 108 ALA H 167 THR H  87	None	1.20A	15.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5w6g	6649 ANTIBODY HEAVY CHAIN (Homo sapiens)	5 / 11	TYR H 157 HIS H 212 LEU H 120 ALA H 180 THR H  92	None	1.19A	12.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 11	TYR A 159 HIS A 160 MET A 357 GLN A 369 PHE A 372	AKJ  A 601 ( 4.7A) None AKJ  A 601 (-3.4A) AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A)	0.70A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	6cbj	DH270.3 FAB HEAVY CHAIN (Homo sapiens)	5 / 11	TYR H 159 HIS H 214 LEU H 122 ALA H 182 THR H  91	None	1.14A	13.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	6db7	HUMAN MONOCLONAL ANTI-HIV-1 GP120 V3 ANTIBODY 1334 FAB HEAVY CHAIN (Homo sapiens)	5 / 11	TYR H 145 HIS H 200 LEU H 108 ALA H 168 THR H  87	None	1.25A	12.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	7fab	IGG1-LAMBDA NEW FAB (HEAVY CHAIN) (Homo sapiens)	5 / 11	TYR H 149 HIS H 204 LEU H 112 ALA H 172 THR H  90	None	1.22A	19.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	5 / 7	TYR A 736 HIS A 737 LEU A 984 GLN A 988 PHE A 991	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A)	0.55A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1spj	KALLIKREIN 1 (Homo sapiens)	4 / 7	TYR A  64 HIS A  35 LEU A  68 VAL A 212	None	1.10A	19.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1x03	SH3-CONTAINING GRB2-LIKE PROTEIN 2 (Homo sapiens)	4 / 7	TYR A 225 HIS A 226 LEU A  68 GLN A  59	None	0.78A	21.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	4 / 7	TYR A 211 HIS A 212 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.64A	27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2o2k	METHIONINE SYNTHASE (Homo sapiens)	4 / 7	TYR A1227 LEU A1097 PHE A1100 VAL A1102	None	1.08A	22.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2o36	THIMET OLIGOPEPTIDASE (Homo sapiens)	4 / 7	TYR A 609 HIS A 600 LEU A 280 VAL A 501	None	1.13A	20.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 7	TYR A 371 HIS A 372 MET A 569 GLN A 581 PHE A 584	NPV  A   3 (-4.4A) NPV  A   3 (-4.6A) NPV  A   3 (-3.1A) NPV  A   3 (-3.1A) NPV  A   3 (-3.3A)	0.81A	29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2z0v	SH3-CONTAINING GRB2-LIKE PROTEIN 3 (Homo sapiens)	4 / 7	TYR A 202 HIS A 203 LEU A  45 GLN A  36	None	1.11A	21.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 7	TYR A 612 HIS A 613 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.46A	93.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 7	TYR A 612 HIS A 613 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.37A	35.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ecn	HIGH AFFINITY CAMP-SPECIFIC AND IBMX-INSENSITIVE 3',5'-CYCLIC PHOSPHODIESTERASE 8A (Homo sapiens)	4 / 7	TYR A 555 HIS A 556 GLN A 778 PHE A 781	None None IBM  A   3 (-3.4A) IBM  A   3 (-3.5A)	0.43A	26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	4 / 7	TYR A 325 HIS A 326 GLN A 535 PHE A 538	None D71  A 901 (-4.5A) D71  A 901 (-3.1A) D71  A 901 (-3.9A)	0.58A	25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 7	TYR A 655 HIS A 656 GLN A 859 PHE A 862	None	0.33A	21.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3n3z	HIGH AFFINITY CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 9A (Homo sapiens)	4 / 7	HIS A 252 GLN A 453 PHE A 456 VAL A 460	None IBM  A   1 (-3.5A) IBM  A   1 (-3.4A) None	0.57A	30.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3n3z	HIGH AFFINITY CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 9A (Homo sapiens)	4 / 7	HIS A 256 GLN A 453 PHE A 456 VAL A 460	ZN  A 507 (-3.8A) IBM  A   1 (-3.5A) IBM  A   1 (-3.4A) None	0.83A	30.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 7	TYR A 233 HIS A 234 GLN A 443 PHE A 446	None None ZG2  A 506 (-3.3A) ZG2  A 506 (-3.6A)	0.53A	28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 7	TYR A 159 HIS A 160 MET A 357 GLN A 369 PHE A 372	TYR  A 159 (-1.3A) HIS  A 160 ( 1.0A) MET  A 357 (-0.0A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A)	0.91A	28.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 7	TYR A 524 HIS A 525 MET A 713 GLN A 726 PHE A 729 VAL A 733	C1L  A   1 ( 4.8A) C1L  A   1 (-4.1A) C1L  A   1 (-3.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A) None	0.57A	42.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ut3	PLASMINOGEN ACTIVATOR INHIBITOR 1 (Homo sapiens)	4 / 7	MET A 235 LEU A 224 PHE A 358 VAL A 376	None	1.06A	22.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4eoz	SPECKLE-TYPE POZ PROTEIN (Homo sapiens)	4 / 7	TYR A 259 LEU A 282 PHE A 251 VAL A 206	None	1.16A	19.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 7	TYR A 655 HIS A 656 MET A 847 GLN A 859 PHE A 862	None	0.42A	35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4j8z	SPECKLE-TYPE POZ PROTEIN (Homo sapiens)	4 / 7	TYR A 259 LEU A 282 PHE A 251 VAL A 206	None	1.16A	20.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 7	TYR A 405 HIS A 406 GLN A 615 PHE A 618	None MG  A 804 ( 4.9A) None None	0.41A	22.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4wzw	PUMILIO DOMAIN-CONTAINING PROTEIN KIAA0020 (Homo sapiens)	4 / 7	MET A 309 GLN A 281 PHE A 280 VAL A 294	None	1.14A	20.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4xwh	ALPHA-N-ACETYLGLUCOS AMINIDASE (Homo sapiens)	4 / 7	HIS A 408 LEU A 563 GLN A 566 VAL A 518	None	1.11A	17.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	4 / 7	TYR A 222 HIS A 223 GLN A 421 PHE A 424	None 4QJ  A 603 ( 4.9A) 4QJ  A 603 (-3.0A) 4QJ  A 603 (-3.5A)	0.57A	27.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 7	TYR A 405 HIS A 406 MET A 603 GLN A 615 PHE A 618	None None 9VE  A 801 (-3.6A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A)	0.62A	13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 7	TYR A 159 HIS A 160 MET A 357 GLN A 369 PHE A 372	AKJ  A 601 ( 4.7A) None AKJ  A 601 (-3.4A) AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A)	0.76A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1hjv	CHITINASE-3 LIKE PROTEIN 1 (Homo sapiens)	5 / 11	ARG A 117 LEU A 153 ALA A  59 PHE A 161 PHE A 119	SO4  A1386 (-4.2A) None None None None	1.18A	22.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	5 / 11	GLN A 962 TYR A 736 HIS A 737 LEU A 984 GLN A 988	None IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) None IBM  A2111 (-3.3A)	1.47A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	6 / 11	TYR A 736 HIS A 737 LEU A 895 LEU A 984 GLN A 988 PHE A 991	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) None None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A)	1.07A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1soj	CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE B (Homo sapiens)	6 / 11	TYR A 736 HIS A 737 LEU A 895 PHE A 959 GLN A 988 PHE A 991	IBM  A2111 (-4.5A) IBM  A2111 ( 4.8A) None None IBM  A2111 (-3.3A) IBM  A2111 (-3.6A)	0.45A	24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1z8l	GLUTAMATE CARBOXYPEPTIDASE II (Homo sapiens)	5 / 11	TYR A 692 HIS A 689 LEU A 671 LEU A 632 PHE A 639	None	1.31A	18.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	1zkl	HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 7A (Homo sapiens)	5 / 11	TYR A 211 HIS A 212 PHE A 384 GLN A 413 PHE A 416	IBM  A 503 (-4.6A) None IBM  A 503 (-4.5A) IBM  A 503 (-3.0A) IBM  A 503 (-3.4A)	0.61A	27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	6 / 11	TYR A 371 HIS A 372 PHE A 552 MET A 569 GLN A 581 PHE A 584	NPV  A   3 (-4.4A) NPV  A   3 (-4.6A) NPV  A   3 (-4.8A) NPV  A   3 (-3.1A) NPV  A   3 (-3.1A) NPV  A   3 (-3.3A)	0.84A	29.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 612 HIS A 613 LEU A 725 ALA A 767 PHE A 786 GLN A 817 PHE A 820	VDN  A   1 (-4.8A) VDN  A   1 (-4.3A) None VDN  A   1 ( 3.8A) None VDN  A   1 (-3.0A) VDN  A   1 (-3.6A)	0.52A	93.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3bjc	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 612 HIS A 613 LEU A 725 ALA A 767 PHE A 786 GLN A 817 PHE A 820	None MG  A 877 (-4.4A) None WAN  A 901 ( 3.9A) WAN  A 901 (-4.8A) WAN  A 901 (-3.1A) WAN  A 901 (-3.7A)	0.44A	35.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3g4g	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	5 / 11	TYR A 325 HIS A 326 PHE A 506 GLN A 535 PHE A 538	None D71  A 901 (-4.5A) D71  A 901 (-4.8A) D71  A 901 (-3.1A) D71  A 901 (-3.9A)	0.63A	25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ibj	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	TYR A 655 HIS A 656 LEU A 770 GLN A 859 PHE A 862	None	0.69A	21.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 PHE A 414 GLN A 443 PHE A 446	None None ZG2  A 506 (-4.4A) ZG2  A 506 (-3.3A) ZG2  A 506 (-3.6A)	0.58A	28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3sl5	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	6 / 11	TYR A 159 HIS A 160 PHE A 340 MET A 357 GLN A 369 PHE A 372	TYR  A 159 (-1.3A) HIS  A 160 ( 1.0A) PHE  A 340 (-1.3A) MET  A 357 (-0.0A) GLN  A 369 (-0.6A) PHE  A 372 (-1.3A)	1.01A	28.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 11	TYR A 524 HIS A 525 LEU A 635 PHE A 696 MET A 713 GLN A 726 PHE A 729	C1L  A   1 ( 4.8A) C1L  A   1 (-4.1A) None C1L  A   1 ( 4.7A) C1L  A   1 (-3.7A) C1L  A   1 (-2.9A) C1L  A   1 (-3.5A)	0.69A	42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 655 HIS A 656 LEU A 770 PHE A 830 MET A 847 GLN A 859 PHE A 862	None	0.66A	35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	TYR A 655 HIS A 656 LEU A 770 PHE A 830 MET A 848	None	1.28A	35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4wzi	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 405 HIS A 406 PHE A 586 GLN A 615 PHE A 618	None MG  A 804 ( 4.9A) None None None	0.46A	22.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 11	TYR A 222 HIS A 223 PHE A 392 GLN A 421 PHE A 424	None 4QJ  A 603 ( 4.9A) GOL  A 607 (-3.9A) 4QJ  A 603 (-3.0A) 4QJ  A 603 (-3.5A)	0.66A	27.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5ohj	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 11	TYR A 405 HIS A 406 PHE A 586 MET A 603 GLN A 615 PHE A 618	None None 9VE  A 801 (-3.6A) 9VE  A 801 (-3.6A) 9VE  A 801 (-3.2A) 9VE  A 801 (-3.9A)	0.72A	13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5wh6	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D (Homo sapiens)	6 / 11	TYR A 159 HIS A 160 PHE A 340 MET A 357 GLN A 369 PHE A 372	AKJ  A 601 ( 4.7A) None AKJ  A 601 (-4.5A) AKJ  A 601 (-3.4A) AKJ  A 601 (-3.0A) AKJ  A 601 (-4.1A)	0.82A	undetectable